Comparing the COVID-19 Mortality Rate in Cancer Patients with and Without a History of Chemotherapy

IF 0.4 Q4 ONCOLOGY

International Journal of Cancer Management Pub Date : 2022-10-16 DOI:10.5812/ijcm-128404

Nasrin Bazgir, F. Taghinezhad, H. Nourmohammadi, Golnaz Azami, I. Ahmadi, A. Mozafari

{"title":"Comparing the COVID-19 Mortality Rate in Cancer Patients with and Without a History of Chemotherapy","authors":"Nasrin Bazgir, F. Taghinezhad, H. Nourmohammadi, Golnaz Azami, I. Ahmadi, A. Mozafari","doi":"10.5812/ijcm-128404","DOIUrl":null,"url":null,"abstract":"Background: Patients with cancer are potentially vulnerable to COVID-19 infection due to the immune-compromised state of cancer or its treatment complications. Objectives: This study compared the COVID-19 mortality rate in cancer patients with and without a history of chemotherapy. Methods: This registry-based cohort study launched from March 2020 to March 2021 contains 2350 records in which 64 COVID-19 patients with cancer were included, of which 27 patients underwent the chemotherapy plan within eight weeks before confirmed COVID-19. In addition, age and sex were matched in patients without a history of cancer as a control group. Two groups of cancer patients with and without a history of chemotherapy compared to the control group using cox proportional hazard regression models in Stata.10 software. Results: Patients with cancer had a higher hazard for in-hospital mortality from COVID-19 infection (adjusted HR; 2.27, 95% CI: 1.25 - 4.13, P = 0.007) after adjusting for age, sex, body mass index (BMI), and co-morbidities. Our result showed no significant association between chemotherapy and control groups (adjusted HR; 1.65, 95% CI: 0.60 - 4.56, P = 0.33). Conclusions: Patients with cancer faced a risk of mortality from COVID-19 two times higher than those without cancer. However, chemotherapy did not increase the mortality following COVID-19 infection.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"132 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-128404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with cancer are potentially vulnerable to COVID-19 infection due to the immune-compromised state of cancer or its treatment complications. Objectives: This study compared the COVID-19 mortality rate in cancer patients with and without a history of chemotherapy. Methods: This registry-based cohort study launched from March 2020 to March 2021 contains 2350 records in which 64 COVID-19 patients with cancer were included, of which 27 patients underwent the chemotherapy plan within eight weeks before confirmed COVID-19. In addition, age and sex were matched in patients without a history of cancer as a control group. Two groups of cancer patients with and without a history of chemotherapy compared to the control group using cox proportional hazard regression models in Stata.10 software. Results: Patients with cancer had a higher hazard for in-hospital mortality from COVID-19 infection (adjusted HR; 2.27, 95% CI: 1.25 - 4.13, P = 0.007) after adjusting for age, sex, body mass index (BMI), and co-morbidities. Our result showed no significant association between chemotherapy and control groups (adjusted HR; 1.65, 95% CI: 0.60 - 4.56, P = 0.33). Conclusions: Patients with cancer faced a risk of mortality from COVID-19 two times higher than those without cancer. However, chemotherapy did not increase the mortality following COVID-19 infection.

查看原文本刊更多论文

有和无化疗史的癌症患者COVID-19死亡率的比较

背景:由于癌症的免疫功能低下状态或其治疗并发症，癌症患者可能容易感染COVID-19。目的:本研究比较有和无化疗史的癌症患者的COVID-19死亡率。方法:本研究于2020年3月至2021年3月启动，纳入2350例病例，其中64例2019冠状病毒病癌症患者，其中27例患者在确诊前8周内接受化疗方案。此外，在没有癌症病史的患者中，年龄和性别相匹配，作为对照组。采用Stata.10软件中的cox比例风险回归模型，将两组有和无化疗史的癌症患者与对照组进行比较。结果:癌症患者因COVID-19感染而住院死亡的风险较高(调整HR;2.27, 95% CI: 1.25 - 4.13, P = 0.007)，校正了年龄、性别、体重指数(BMI)和合并症。我们的结果显示化疗组与对照组之间无显著关联(校正HR;1.65, 95% ci: 0.60 - 4.56, p = 0.33)。结论:癌症患者的COVID-19死亡风险是非癌症患者的两倍。然而，化疗并没有增加COVID-19感染后的死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Cancer Management ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.